Avid stock market watchers will know the biotech space operates according to a different rule set. One session can wipe off a huge chunk of a stock’s valuation, if clinical testing goes awry or the regulators pick holes in a drug’s development. Yet, the opposite also holds true; shares can deliver unseemly gains if the news flow is decidedly positive. Fortunately for Veru$Veru Inc.(VERU)$ investors, this week saw plenty of the latter. Shares soared by 182% in one session, after the company announced positive data from a phase 3 clinical trial of its Covid-19 treatment, sabizabulin. In fact, the data was so good, that the company announced it was halting the late-stage testing. An interim analysis of hospitalized patients with moderate to severe COVID